Jane Street Group LLC Has $1.63 Million Stock Holdings in Artivion, Inc. (NYSE:AORT)

Jane Street Group LLC raised its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 69.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,035 shares of the company's stock after acquiring an additional 24,945 shares during the period. Jane Street Group LLC owned 0.15% of Artivion worth $1,625,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company increased its holdings in shares of Artivion by 3.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company's stock worth $392,000 after acquiring an additional 481 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Artivion by 3.1% in the second quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company's stock valued at $510,000 after purchasing an additional 600 shares during the period. Intech Investment Management LLC raised its holdings in shares of Artivion by 6.6% during the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock valued at $280,000 after buying an additional 653 shares during the last quarter. Quarry LP raised its holdings in shares of Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company's stock valued at $32,000 after buying an additional 820 shares during the last quarter. Finally, nVerses Capital LLC acquired a new position in shares of Artivion during the second quarter worth approximately $28,000. 86.37% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Artivion news, CAO Amy Horton sold 4,329 shares of the company's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now owns 135,660 shares of the company's stock, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jean F. Holloway sold 8,070 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares of the company's stock, valued at approximately $4,634,323.44. This represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,447 shares of company stock valued at $925,424 over the last three months. Company insiders own 8.10% of the company's stock.

Analysts Set New Price Targets

AORT has been the topic of several analyst reports. JMP Securities restated a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Stifel Nicolaus raised their price target on Artivion from $28.00 to $30.00 and gave the company a "buy" rating in a report on Friday, September 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Artivion in a report on Monday, December 9th. Finally, Oppenheimer increased their target price on shares of Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion presently has an average rating of "Buy" and an average target price of $31.80.

Artivion Price Performance

Shares of AORT traded down $0.34 during midday trading on Friday, reaching $29.00. The stock had a trading volume of 147,676 shares, compared to its average volume of 228,003. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The company has a market capitalization of $1.22 billion, a P/E ratio of -1,450.00 and a beta of 1.75. The firm's 50 day moving average price is $28.15 and its 200-day moving average price is $26.51. Artivion, Inc. has a 52 week low of $16.48 and a 52 week high of $30.45.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.